Remdesivir is a broad-spectrum antiviral prodrug that gained global attention for its emergency use in the treatment of COVID-19. It is a monophosphoramidate prodrug of an adenosine analog, which gets metabolized intracellularly to its active triphosphate form. This active form inhibits the viral RNA-dependent RNA polymerase (RdRp), thereby halting viral replication.
Indications include:
∙ Treatment of COVID-19 in hospitalized patients
∙ Investigational use for other viral infections like Ebola and Marburg (earlier studies)
Remdesivir is administered intravenously and is typically used under strict clinical protocols in hospital settings.
Parent: Remdesivir
Parent: Remdesivir
Parent: Remdesivir
Impurities in Remdesivir originate from its complex multi-step chemical synthesis, including nucleoside analog construction and phosphoramidate linkage, as well as from potential degradation during storage or formulation. All impurities must comply with ICH Q3A/B and pharmacopeial requirements to ensure product quality and patient safety.
Types of Impurities in Remdesivir
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Remdesivir is primarily used for the treatment of hospitalized patients with moderate to severe COVID-19 infections. It was the first antiviral drug approved for COVID-19 in many countries under emergency use authorization.
It is metabolized into an active nucleoside triphosphate analog, which inhibits viral RNA polymerase, blocking the replication of viral genetic material.
Use in pregnancy and pediatric patients should be considered only when the benefits outweigh the risks, and under strict medical supervision. Data in these populations is still limited.
Yes, it should be stored in its lyophilized or solution form under recommended temperature conditions, away from light and moisture. Stability is critical due to its susceptibility to hydrolysis.
